Derazantinib
PreclinicalSmall molecule
Basilea PharmaceuticaDerazantinib is one of 79 small molecule programs targeting Gastric Adenocarcinoma. It is currently in Preclinical.
2
Indications
5
Total Trials
1
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
150 competitors in Gastric Adenocarcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Eloxatin
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Camptosar
PfizerPhase 3
Elunate
TakedaPhase 3
Taxotere
AAvyxa
Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Intrahepatic Cholangiocarcinoma2 trials
Gastric Adenocarcinoma1 trial
FGFR2 Fusions1 trial
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05174650·27 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Derazantinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company